Legend Biotech Reports 50% Of CARTITUDE-2 Patients Remained Progression-Free At 5 Years After Single CARVYKTI Infusion
Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMMBRIDGEWATER, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Legend Biotech